Ekso Bionics Q3 revenue $4.2M (+2% YoY); exploring sale or acquisition of different industry

EKSO BIONICS HOLDINGS, INC.

Revenue $4.2M, up 2% YoY and 105% sequentially; gross margin 60.3% vs 53.5% last year.
Net loss narrowed 31% YoY to $1.4M ($0.54/share) from $2.1M ($1.53/share).
Cash $2.7M as of Sept 30, 2025.
Company exploring strategic transactions including acquisition of a non-exoskeleton business or sale of substantially all assets.
Any transaction would require stockholder approval; no timetable set for strategic review.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.